|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF557 |
Gene summary for ZNF557 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF557 | Gene ID | 79230 |
| Gene name | zinc finger protein 557 | |
| Gene Alias | ZNF557 | |
| Cytomap | 19p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q8N988 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79230 | ZNF557 | HCC1_Meng | Human | Liver | HCC | 2.43e-17 | -2.94e-02 | 0.0246 |
| 79230 | ZNF557 | HCC2_Meng | Human | Liver | HCC | 7.62e-07 | -1.34e-02 | 0.0107 |
| 79230 | ZNF557 | HCC1 | Human | Liver | HCC | 2.02e-06 | 2.80e+00 | 0.5336 |
| 79230 | ZNF557 | HCC2 | Human | Liver | HCC | 1.91e-13 | 1.53e+00 | 0.5341 |
| 79230 | ZNF557 | HCC5 | Human | Liver | HCC | 9.70e-07 | 8.72e-01 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF557 | BN | Liver | Cirrhotic | LINC01138,TKT,CHST12, etc. | 1.09e-01 |  |
| ZNF557 | MEGA | Lung | ADJ | TMEM86A,AC147067.1,FLT1, etc. | 3.35e-02 |  |
| ZNF557 | FIB | Lung | Healthy | TMEM86A,AC147067.1,FLT1, etc. | 4.45e-01 |  |
| ZNF557 | PVA | Lung | Healthy | TMEM86A,AC147067.1,FLT1, etc. | 1.08e-01 | |
| ZNF557 | PVA | Lung | IAC | TMEM86A,AC147067.1,FLT1, etc. | 1.51e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF557 | SNV | Missense_Mutation | c.31N>T | p.Ala11Ser | p.A11S | Q8N988 | protein_coding | tolerated(0.27) | probably_damaging(0.962) | TCGA-AP-A0LT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF557 | SNV | Missense_Mutation | c.872A>G | p.His291Arg | p.H291R | Q8N988 | protein_coding | tolerated(0.09) | benign(0.352) | TCGA-AP-A1DP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | paclitaxel | PD | |
| ZNF557 | SNV | Missense_Mutation | rs569224650 | c.811N>T | p.Arg271Cys | p.R271C | Q8N988 | protein_coding | deleterious(0) | benign(0.129) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| ZNF557 | SNV | Missense_Mutation | novel | c.1103N>T | p.Arg368Ile | p.R368I | Q8N988 | protein_coding | deleterious(0) | possibly_damaging(0.753) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| ZNF557 | SNV | Missense_Mutation | c.998N>T | p.Ser333Leu | p.S333L | Q8N988 | protein_coding | tolerated(0.12) | benign(0.062) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF557 | SNV | Missense_Mutation | novel | c.439N>A | p.Leu147Ile | p.L147I | Q8N988 | protein_coding | tolerated(0.43) | possibly_damaging(0.556) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| ZNF557 | SNV | Missense_Mutation | c.259G>A | p.Asp87Asn | p.D87N | Q8N988 | protein_coding | tolerated(0.2) | benign(0) | TCGA-B5-A11R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
| ZNF557 | SNV | Missense_Mutation | rs569224650 | c.811C>T | p.Arg271Cys | p.R271C | Q8N988 | protein_coding | deleterious(0) | benign(0.129) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF557 | SNV | Missense_Mutation | novel | c.1181A>G | p.His394Arg | p.H394R | Q8N988 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF557 | SNV | Missense_Mutation | novel | c.1210N>C | p.Tyr404His | p.Y404H | Q8N988 | protein_coding | deleterious(0.04) | benign(0.001) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |